- Home
- ICON vs GRI Comparison
ICON vs GRI Comparison
Compare ICON & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- GRI
- Stock Information
- Founded
- ICON 2023
- GRI 2018
- Country
- ICON Greece
- GRI United States
- Employees
- ICON N/A
- GRI N/A
- Industry
- ICON
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- GRI Health Care
- Exchange
- ICON Nasdaq
- GRI Nasdaq
- Market Cap
- ICON 3.4M
- GRI 3.0M
- IPO Year
- ICON 2024
- GRI N/A
- Fundamental
- Price
- ICON $2.78
- GRI $0.69
- Analyst Decision
- ICON Strong Buy
- GRI Strong Buy
- Analyst Count
- ICON 1
- GRI 1
- Target Price
- ICON $7.00
- GRI $12.00
- AVG Volume (30 Days)
- ICON 33.5K
- GRI 3.4M
- Earning Date
- ICON 12-03-2024
- GRI 11-14-2024
- Dividend Yield
- ICON 2.88%
- GRI N/A
- EPS Growth
- ICON N/A
- GRI N/A
- EPS
- ICON 0.35
- GRI N/A
- Revenue
- ICON $4,810,000.00
- GRI N/A
- Revenue This Year
- ICON $64.08
- GRI N/A
- Revenue Next Year
- ICON $100.00
- GRI N/A
- P/E Ratio
- ICON $8.01
- GRI N/A
- Revenue Growth
- ICON 5.71
- GRI N/A
- 52 Week Low
- ICON $1.81
- GRI $0.30
- 52 Week High
- ICON $3.85
- GRI $106.29
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- GRI 46.42
- Support Level
- ICON N/A
- GRI $0.62
- Resistance Level
- ICON N/A
- GRI $1.00
- Average True Range (ATR)
- ICON 0.00
- GRI 0.10
- MACD
- ICON 0.00
- GRI -0.04
- Stochastic Oscillator
- ICON 0.00
- GRI 16.42
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.